Technetium-labeled myocardial perfusion agents.
Since its approval for clinical use in 1975, thallium-201 has been the mainstay for myocardial perfusion imaging to diagnose and manage patients with coronary artery disease. In 1992, 80% of 2.6 million myocardial perfusion imaging studies were done with thallium-201. Thallium-201 has important limitations, however, related to photon energy, half life, and availability. In December 1990, two Tc-99m-labeled agents (sestamibi and teboroxime) were approved for clinical use. There are ongoing clinical trials with other classes of Tc-99m agents. This article describes kinetics and imaging experience with Tc-99m-labeled perfusion agents.
Philadelphia Heart Institute, Presbyterian Medical Center, Pennsylvania.
J
J
Heo
A S
AS
Iskandrian
D000818:Animals; D002985:Clinical Protocols; D003327:Coronary Disease / Q000000981:diagnostic imaging* / Q000503:physiopathology; D006321:Heart / Q000000981:diagnostic imaging* / Q000503:physiopathology; D006801:Humans; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics; D010091:Oximes; D017256:Technetium Tc 99m Sestamibi; D013794:Thallium Radioisotopes; D015899:Tomography, Emission-Computed, Single-Photon
D015609:Organotechnetium Compounds; D010091:Oximes; D013794:Thallium Radioisotopes; C081873:technetium Tc 94m teboroxime; D017256:Technetium Tc 99m Sestamibi